Literature DB >> 2252306

The 5-HT1B receptors.

D N Middlemiss1, P H Hutson.   

Abstract

The 5-HT1B receptors have been identified by radioligand binding techniques predominantly in the basal ganglia of the rat and mouse brain. A number of 5-HT receptor agonists have been shown to display high affinity but limited selectivity for the 5-HT1B recognition site. These include 5-CT, 5-HT, RU 24969, TFMPP, MCPP, and CGS 12066B. Antagonists at the 5-HT1B site include the drugs metitepin, metergoline, cyanopindolol, isamoltane, and propranolol but none of these drugs are selective for this receptor. Functional correlates of 5-HT1B receptor activation have been most closely defined in vitro. These include inhibition of transmitter release, inhibition of forskolin-stimulated adenylate cyclase and actions on the mouse urinary bladder strip and the rat vena cava. Many functional correlates of 5-HT1B receptor activation in vivo have been proposed, but convincing evidence from antagonist studies is generally lacking. The development of selective 5-HT1B receptor agonists and antagonists will be a key step in defining the physiological role of this receptor site in the brain and periphery of the mouse and rat although it must be realized that these compounds, if they are developed, are unlikely to have functional effects in man since the 5-HT1B recognition site is absent in the human CNS. Nevertheless many of these studies on the 5-HT1B receptor may aid the development of drugs acting at the 5-HT1D site since this receptor has been identified as being the equivalent of the 5-HT1B site in species other than the rat and mouse.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2252306     DOI: 10.1111/j.1749-6632.1990.tb16878.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  11 in total

1.  5-HT1B autoreceptors differentially modulate the expression of conditioned fear in a circuit-specific manner.

Authors:  Y Liu; M A Kelly; T J Sexton; J F Neumaier
Journal:  Neuroscience       Date:  2015-04-20       Impact factor: 3.590

2.  Functional characterization of the 5-HT terminal autoreceptor in the guinea-pig brain cortex.

Authors:  C Roberts; J Watson; M Burton; G W Price; B J Jones
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

3.  5-HT1B Receptor-Mediated Activation of ERK1/2 Requires Both Gαi/o and β-Arrestin Proteins.

Authors:  Yusha Liu; Alec W Gibson; Marjorie R Levinstein; Atom J Lesiak; Shao-En Ong; John F Neumaier
Journal:  ACS Chem Neurosci       Date:  2019-04-29       Impact factor: 4.418

4.  Astroglial Serotonin Receptors as the Central Target of Classic Antidepressants.

Authors:  Alexei Verkhratsky; Vladimir Parpura; Caterina Scuderi; Baoman Li
Journal:  Adv Neurobiol       Date:  2021

5.  Serotonergic influences on male sexual behavior of rhesus monkeys: effects of serotonin agonists.

Authors:  S M Pomerantz; B C Hepner; J M Wertz
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  [3H]-5-carboxamidotryptamine labels 5-HT1D binding sites in bovine substantia nigra.

Authors:  H P Nowak; C D Mahle; F D Yocca
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

7.  A genetic rat model of depression, Flinders sensitive line, has a lower density of 5-HT(1A) receptors, but a higher density of 5-HT(1B) receptors, compared to control rats.

Authors:  Kyoko Nishi; Kazuya Kanemaru; Mirko Diksic
Journal:  Neurochem Int       Date:  2008-12-13       Impact factor: 3.921

Review 8.  Targeted 5-HT1F Therapies for Migraine.

Authors:  Marta Vila-Pueyo
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

Review 9.  The 5-HT1B receptor - a potential target for antidepressant treatment.

Authors:  Mikael Tiger; Katarina Varnäs; Yoshiro Okubo; Johan Lundberg
Journal:  Psychopharmacology (Berl)       Date:  2018-03-15       Impact factor: 4.530

10.  First Evidence of Kv3.1b Potassium Channel Subtype Expression during Neuronal Serotonergic 1C11 Cell Line Development.

Authors:  Hager Tabka; Amani Cheikh; Sonia Maatoug; Mohamed El Ayeb; Saïd Bendahhou; Rym Benkhalifa
Journal:  Int J Mol Sci       Date:  2020-09-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.